Literature DB >> 25914611

Navigating the road ahead: addressing challenges for use of metabolomics in epidemiology studies.

Majda Haznadar1, Padma Maruvada2, Eliza Mette3, John Milner4, Steven C Moore5, Holly L Nicastro6, Joshua N Sampson5, L Joseph Su3, Mukesh Verma3, Krista A Zanetti3.   

Abstract

Metabolomics platforms allow for the measurement of hundreds to thousands of unique small chemical entities, as well as offer extensive coverage of metabolic markers related to obesity, diet, smoking, and other exposures of high interest to health scientists. Nevertheless, its potential use as a tool in population-based study design has not been fully explored. As the field of metabolomics continues to mature, and in part, accelerate through the National Institutes of Health (NIH) investment of ≤65 million in the Common Fund's Metabolomics Program (https://common fund.nih.gov/metabolomics/index), it is time to consider those challenges most pertinent to epidemiologic studies.

Entities:  

Year:  2014        PMID: 25914611      PMCID: PMC4407369          DOI: 10.1007/s11306-014-0636-z

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  7 in total

1.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

Authors:  C Schairer; J Lubin; R Troisi; S Sturgeon; L Brinton; R Hoover
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

2.  Multiplicities in cancer research: ubiquitous and necessary evils.

Authors:  Donald Berry
Journal:  J Natl Cancer Inst       Date:  2012-08-02       Impact factor: 13.506

3.  Nested case-control studies.

Authors:  V L Ernster
Journal:  Prev Med       Date:  1994-09       Impact factor: 4.018

4.  Cancer biomarkers: can we turn recent failures into success?

Authors:  Eleftherios P Diamandis
Journal:  J Natl Cancer Inst       Date:  2010-08-12       Impact factor: 13.506

5.  Metabolomics in epidemiology: sources of variability in metabolite measurements and implications.

Authors:  Joshua N Sampson; Simina M Boca; Xiao Ou Shu; Rachael Z Stolzenberg-Solomon; Charles E Matthews; Ann W Hsing; Yu Ting Tan; Bu-Tian Ji; Wong-Ho Chow; Qiuyin Cai; Da Ke Liu; Gong Yang; Yong Bing Xiang; Wei Zheng; Rashmi Sinha; Amanda J Cross; Steven C Moore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-02-08       Impact factor: 4.254

6.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China.

Authors:  G S Qian; R K Ross; M C Yu; J M Yuan; Y T Gao; B E Henderson; G N Wogan; J D Groopman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994 Jan-Feb       Impact factor: 4.254

7.  The role of reporting standards for metabolite annotation and identification in metabolomic studies.

Authors:  Reza M Salek; Christoph Steinbeck; Mark R Viant; Royston Goodacre; Warwick B Dunn
Journal:  Gigascience       Date:  2013-10-16       Impact factor: 6.524

  7 in total
  3 in total

Review 1.  Mechanistic and Technical Challenges in Studying the Human Microbiome and Cancer Epidemiology.

Authors:  Mukesh Verma
Journal:  Technol Cancer Res Treat       Date:  2016-06-22

Review 2.  Building infrastructure at the National Cancer Institute to support metabolomic analyses in epidemiological studies.

Authors:  Krista A Zanetti
Journal:  Metabolomics       Date:  2021-05-03       Impact factor: 4.290

3.  Alcohol Consumption-Related Metabolites in Relation to Colorectal Cancer and Adenoma: Two Case-Control Studies Using Serum Biomarkers.

Authors:  Jose Ramon Troche; Susan T Mayne; Neal D Freedman; Fatma M Shebl; Kristin A Guertin; Amanda J Cross; Christian C Abnet
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.